inPractice® - Integrase Inhibitors

Special Considerations and Clinical Management of HIV in Patients With Substance Use Disorder

Author: Frederick L. Altice, MD (More Info)
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 2/5/20 (What's New)

Summary

Administration of raltegravir has no significant effect on methadone^{[FDA Raltegravir]} or buprenorphine/naloxone^{[Douglas Bruce 2013]}
No significant interactions occur with coadministration of elvitegravir, cobicistat, and methadone^{[Bruce 2013c]} or buprenorphine/naloxone^{[Bruce 2013b]}
No significant interactions occur between dolutegravir and methadone^{[Song 2013]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Initial Antiretroviral Therapy, IV Drug Use, Special Populations